Nivatrotamab
- Generic Name
- Nivatrotamab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2278244-14-5
- Unique Ingredient Identifier
- 8RV18E4A94
- Background
Nivatrotamab is under investigation in clinical trial NCT03860207 (Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3f8-bsab) in Patients With Relapsed/refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers).
- Associated Conditions
- -
- Associated Therapies
- -
Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer
- First Posted Date
- 2021-02-11
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Y-mAbs Therapeutics
- Target Recruit Count
- 3
- Registration Number
- NCT04750239
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Emory University, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath